Default company panoramic image
Logo

Solaris Therapeutics

Early stage therapeutics company focused on small-molecule inhibitors of E3 ligases; novel oral antidiabetic in preclinical development.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Doylestown, PA, USA
  • Currency USD
  • Employees 1
  • Website solarisrx.com

Company Summary

Solaris develops drugs against the E3 ligase family of proteins, implicated in diseases across multiple therapeutic areas. Our lead, a novel oral antidiabetic shown to improve glucose control and insulin responsiveness, is 2 years and $1MM from clinical candidate stage, when it will be an attractive partnering target for global pharmaceutical companies. Potential follow-ons are being considered in oncology, CNS, and anti-infective diseases.

Team

  • Default avatar
    Richard Christie
    CEO

  • Default avatar
    Brent Stockwell
    Founder

  • Default avatar
    Michael Foley
    Founder

Advisors

  • Default avatar
    Liang Law Office; Riverside Law
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    BioAdvance
    Unconfirmed
    Default avatar
    SBIR Phase I grant recently awarded
    Unconfirmed